nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexamethasone—PTGS2—urinary bladder cancer	0.143	1	CbGaD
Dexamethasone—NOS2—Doxorubicin—urinary bladder cancer	0.0781	0.146	CbGbCtD
Dexamethasone—CYP4A11—Cisplatin—urinary bladder cancer	0.0669	0.125	CbGbCtD
Dexamethasone—CYP2B6—Thiotepa—urinary bladder cancer	0.0337	0.0631	CbGbCtD
Dexamethasone—ABCB1—Mitomycin—urinary bladder cancer	0.0228	0.0427	CbGbCtD
Dexamethasone—ABCB11—Doxorubicin—urinary bladder cancer	0.0186	0.0349	CbGbCtD
Dexamethasone—CYP1B1—Doxorubicin—urinary bladder cancer	0.0186	0.0349	CbGbCtD
Dexamethasone—ABCC2—Carboplatin—urinary bladder cancer	0.0171	0.032	CbGbCtD
Dexamethasone—CYP2A6—Fluorouracil—urinary bladder cancer	0.0168	0.0315	CbGbCtD
Dexamethasone—ABCG2—Fluorouracil—urinary bladder cancer	0.0156	0.0291	CbGbCtD
Dexamethasone—ABCG2—Carboplatin—urinary bladder cancer	0.0155	0.029	CbGbCtD
Dexamethasone—ABCC2—Cisplatin—urinary bladder cancer	0.0146	0.0274	CbGbCtD
Dexamethasone—PTGS2—Cisplatin—urinary bladder cancer	0.0144	0.0271	CbGbCtD
Dexamethasone—ABCC2—Etoposide—urinary bladder cancer	0.0144	0.0269	CbGbCtD
Dexamethasone—PTGS2—Etoposide—urinary bladder cancer	0.0142	0.0266	CbGbCtD
Dexamethasone—ABCG2—Cisplatin—urinary bladder cancer	0.0132	0.0248	CbGbCtD
Dexamethasone—ABCG2—Etoposide—urinary bladder cancer	0.013	0.0243	CbGbCtD
Dexamethasone—SLCO1A2—Methotrexate—urinary bladder cancer	0.0114	0.0214	CbGbCtD
Dexamethasone—CYP3A4—Thiotepa—urinary bladder cancer	0.0103	0.0194	CbGbCtD
Dexamethasone—ABCC2—Doxorubicin—urinary bladder cancer	0.0098	0.0183	CbGbCtD
Dexamethasone—ABCC2—Methotrexate—urinary bladder cancer	0.00949	0.0178	CbGbCtD
Dexamethasone—CYP2B6—Cisplatin—urinary bladder cancer	0.00929	0.0174	CbGbCtD
Dexamethasone—CYP2E1—Etoposide—urinary bladder cancer	0.00926	0.0173	CbGbCtD
Dexamethasone—ABCG2—Doxorubicin—urinary bladder cancer	0.00886	0.0166	CbGbCtD
Dexamethasone—ABCG2—Methotrexate—urinary bladder cancer	0.00858	0.0161	CbGbCtD
Dexamethasone—CYP2C8—Fluorouracil—urinary bladder cancer	0.00829	0.0155	CbGbCtD
Dexamethasone—CYP3A5—Etoposide—urinary bladder cancer	0.00719	0.0135	CbGbCtD
Dexamethasone—CYP2C8—Etoposide—urinary bladder cancer	0.00692	0.013	CbGbCtD
Dexamethasone—ABCB1—Gemcitabine—urinary bladder cancer	0.00656	0.0123	CbGbCtD
Dexamethasone—CYP2B6—Doxorubicin—urinary bladder cancer	0.00623	0.0117	CbGbCtD
Dexamethasone—CYP2C9—Fluorouracil—urinary bladder cancer	0.00578	0.0108	CbGbCtD
Dexamethasone—CYP2C9—Cisplatin—urinary bladder cancer	0.00491	0.0092	CbGbCtD
Dexamethasone—ABCB1—Cisplatin—urinary bladder cancer	0.00476	0.00893	CbGbCtD
Dexamethasone—ABCB1—Etoposide—urinary bladder cancer	0.00468	0.00877	CbGbCtD
Dexamethasone—ABCB1—Doxorubicin—urinary bladder cancer	0.00319	0.00598	CbGbCtD
Dexamethasone—ABCB1—Methotrexate—urinary bladder cancer	0.00309	0.00579	CbGbCtD
Dexamethasone—CYP2D6—Doxorubicin—urinary bladder cancer	0.00301	0.00564	CbGbCtD
Dexamethasone—CYP3A4—Etoposide—urinary bladder cancer	0.0028	0.00525	CbGbCtD
Dexamethasone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00191	0.00358	CbGbCtD
Dexamethasone—CYP2C19—urine—urinary bladder cancer	0.00186	0.0292	CbGeAlD
Dexamethasone—CYP4A11—renal system—urinary bladder cancer	0.00161	0.0254	CbGeAlD
Dexamethasone—NR0B1—female reproductive system—urinary bladder cancer	0.0015	0.0236	CbGeAlD
Dexamethasone—ANXA1—prostate gland—urinary bladder cancer	0.0015	0.0236	CbGeAlD
Dexamethasone—NR3C1—urine—urinary bladder cancer	0.00145	0.0228	CbGeAlD
Dexamethasone—PLA2G1B—epithelium—urinary bladder cancer	0.00144	0.0227	CbGeAlD
Dexamethasone—CYP2C9—urine—urinary bladder cancer	0.00144	0.0226	CbGeAlD
Dexamethasone—CYP2E1—urine—urinary bladder cancer	0.00136	0.0215	CbGeAlD
Dexamethasone—PLA2G1B—renal system—urinary bladder cancer	0.00134	0.021	CbGeAlD
Dexamethasone—ANXA1—seminal vesicle—urinary bladder cancer	0.00127	0.02	CbGeAlD
Dexamethasone—CYP4A11—vagina—urinary bladder cancer	0.00117	0.0184	CbGeAlD
Dexamethasone—ANXA1—epithelium—urinary bladder cancer	0.0011	0.0173	CbGeAlD
Dexamethasone—CYP3A4—urine—urinary bladder cancer	0.0011	0.0173	CbGeAlD
Dexamethasone—CYP2D6—urine—urinary bladder cancer	0.00108	0.017	CbGeAlD
Dexamethasone—PLA2G1B—female reproductive system—urinary bladder cancer	0.00107	0.0168	CbGeAlD
Dexamethasone—ANXA1—smooth muscle tissue—urinary bladder cancer	0.00106	0.0167	CbGeAlD
Dexamethasone—CYP2A6—prostate gland—urinary bladder cancer	0.00104	0.0163	CbGeAlD
Dexamethasone—ANXA1—renal system—urinary bladder cancer	0.00102	0.0161	CbGeAlD
Dexamethasone—ANXA1—urethra—urinary bladder cancer	0.001	0.0158	CbGeAlD
Dexamethasone—NR3C2—prostate gland—urinary bladder cancer	0.000971	0.0153	CbGeAlD
Dexamethasone—CYP17A1—renal system—urinary bladder cancer	0.000916	0.0144	CbGeAlD
Dexamethasone—PGR—prostate gland—urinary bladder cancer	0.000903	0.0142	CbGeAlD
Dexamethasone—CYP2A6—seminal vesicle—urinary bladder cancer	0.000876	0.0138	CbGeAlD
Dexamethasone—NR3C2—seminal vesicle—urinary bladder cancer	0.000821	0.0129	CbGeAlD
Dexamethasone—ANXA1—female reproductive system—urinary bladder cancer	0.000818	0.0129	CbGeAlD
Dexamethasone—CYP19A1—prostate gland—urinary bladder cancer	0.000812	0.0128	CbGeAlD
Dexamethasone—ABCC2—prostate gland—urinary bladder cancer	0.000775	0.0122	CbGeAlD
Dexamethasone—CYP1B1—prostate gland—urinary bladder cancer	0.000759	0.012	CbGeAlD
Dexamethasone—ANXA1—vagina—urinary bladder cancer	0.00074	0.0117	CbGeAlD
Dexamethasone—CYP17A1—female reproductive system—urinary bladder cancer	0.000733	0.0115	CbGeAlD
Dexamethasone—NR3C2—smooth muscle tissue—urinary bladder cancer	0.000687	0.0108	CbGeAlD
Dexamethasone—CYP11A1—female reproductive system—urinary bladder cancer	0.000682	0.0107	CbGeAlD
Dexamethasone—PGR—epithelium—urinary bladder cancer	0.000663	0.0104	CbGeAlD
Dexamethasone—NR3C2—renal system—urinary bladder cancer	0.000662	0.0104	CbGeAlD
Dexamethasone—NR3C2—urethra—urinary bladder cancer	0.00065	0.0102	CbGeAlD
Dexamethasone—PGR—smooth muscle tissue—urinary bladder cancer	0.000639	0.0101	CbGeAlD
Dexamethasone—SLCO1A2—renal system—urinary bladder cancer	0.000567	0.00893	CbGeAlD
Dexamethasone—ABCG2—prostate gland—urinary bladder cancer	0.000565	0.0089	CbGeAlD
Dexamethasone—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.000538	0.00846	CbGeAlD
Dexamethasone—NR3C2—female reproductive system—urinary bladder cancer	0.00053	0.00834	CbGeAlD
Dexamethasone—ABCC2—renal system—urinary bladder cancer	0.000528	0.00832	CbGeAlD
Dexamethasone—CYP3A5—prostate gland—urinary bladder cancer	0.000525	0.00826	CbGeAlD
Dexamethasone—NR3C1—prostate gland—urinary bladder cancer	0.000521	0.0082	CbGeAlD
Dexamethasone—CYP1B1—renal system—urinary bladder cancer	0.000518	0.00815	CbGeAlD
Dexamethasone—CYP2A6—vagina—urinary bladder cancer	0.000511	0.00805	CbGeAlD
Dexamethasone—PGR—female reproductive system—urinary bladder cancer	0.000493	0.00775	CbGeAlD
Dexamethasone—CYP2E1—prostate gland—urinary bladder cancer	0.000489	0.0077	CbGeAlD
Dexamethasone—NR3C2—vagina—urinary bladder cancer	0.000479	0.00754	CbGeAlD
Dexamethasone—ANXA1—lymph node—urinary bladder cancer	0.000479	0.00754	CbGeAlD
Dexamethasone—ABCG2—seminal vesicle—urinary bladder cancer	0.000478	0.00753	CbGeAlD
Dexamethasone—PTGS2—prostate gland—urinary bladder cancer	0.000451	0.00709	CbGeAlD
Dexamethasone—PGR—vagina—urinary bladder cancer	0.000446	0.00701	CbGeAlD
Dexamethasone—CYP19A1—female reproductive system—urinary bladder cancer	0.000443	0.00698	CbGeAlD
Dexamethasone—NR3C1—seminal vesicle—urinary bladder cancer	0.00044	0.00693	CbGeAlD
Dexamethasone—CYP17A1—lymph node—urinary bladder cancer	0.000429	0.00675	CbGeAlD
Dexamethasone—ABCC2—female reproductive system—urinary bladder cancer	0.000423	0.00666	CbGeAlD
Dexamethasone—CYP1B1—female reproductive system—urinary bladder cancer	0.000414	0.00652	CbGeAlD
Dexamethasone—CYP2E1—seminal vesicle—urinary bladder cancer	0.000414	0.00652	CbGeAlD
Dexamethasone—CYP11A1—lymph node—urinary bladder cancer	0.000399	0.00628	CbGeAlD
Dexamethasone—CYP2C8—renal system—urinary bladder cancer	0.000396	0.00624	CbGeAlD
Dexamethasone—CYP1A1—epithelium—urinary bladder cancer	0.000394	0.00621	CbGeAlD
Dexamethasone—NR3C1—epithelium—urinary bladder cancer	0.000383	0.00602	CbGeAlD
Dexamethasone—PTGS2—seminal vesicle—urinary bladder cancer	0.000381	0.006	CbGeAlD
Dexamethasone—ABCG2—urethra—urinary bladder cancer	0.000379	0.00596	CbGeAlD
Dexamethasone—NR3C1—smooth muscle tissue—urinary bladder cancer	0.000369	0.0058	CbGeAlD
Dexamethasone—CYP1A1—renal system—urinary bladder cancer	0.000366	0.00576	CbGeAlD
Dexamethasone—CYP1A1—urethra—urinary bladder cancer	0.000359	0.00566	CbGeAlD
Dexamethasone—CYP3A5—renal system—urinary bladder cancer	0.000358	0.00563	CbGeAlD
Dexamethasone—CYP2B6—renal system—urinary bladder cancer	0.000356	0.0056	CbGeAlD
Dexamethasone—NR3C1—renal system—urinary bladder cancer	0.000355	0.00559	CbGeAlD
Dexamethasone—NR3C1—urethra—urinary bladder cancer	0.000349	0.00549	CbGeAlD
Dexamethasone—CYP2E1—renal system—urinary bladder cancer	0.000334	0.00525	CbGeAlD
Dexamethasone—PTGS2—epithelium—urinary bladder cancer	0.000331	0.00521	CbGeAlD
Dexamethasone—CYP2C19—vagina—urinary bladder cancer	0.000329	0.00518	CbGeAlD
Dexamethasone—CYP2E1—urethra—urinary bladder cancer	0.000328	0.00516	CbGeAlD
Dexamethasone—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000319	0.00502	CbGeAlD
Dexamethasone—CYP2C8—female reproductive system—urinary bladder cancer	0.000317	0.005	CbGeAlD
Dexamethasone—NR3C2—lymph node—urinary bladder cancer	0.00031	0.00488	CbGeAlD
Dexamethasone—PTGS2—renal system—urinary bladder cancer	0.000307	0.00484	CbGeAlD
Dexamethasone—PTGS2—urethra—urinary bladder cancer	0.000302	0.00475	CbGeAlD
Dexamethasone—CYP1A1—female reproductive system—urinary bladder cancer	0.000293	0.00461	CbGeAlD
Dexamethasone—PGR—lymph node—urinary bladder cancer	0.000288	0.00454	CbGeAlD
Dexamethasone—CYP2C8—vagina—urinary bladder cancer	0.000287	0.00452	CbGeAlD
Dexamethasone—CYP2B6—female reproductive system—urinary bladder cancer	0.000285	0.00448	CbGeAlD
Dexamethasone—NR3C1—female reproductive system—urinary bladder cancer	0.000284	0.00447	CbGeAlD
Dexamethasone—CYP2C9—female reproductive system—urinary bladder cancer	0.000282	0.00444	CbGeAlD
Dexamethasone—ABCG2—vagina—urinary bladder cancer	0.000279	0.00439	CbGeAlD
Dexamethasone—ABCB1—prostate gland—urinary bladder cancer	0.000279	0.00439	CbGeAlD
Dexamethasone—CYP3A4—renal system—urinary bladder cancer	0.000268	0.00423	CbGeAlD
Dexamethasone—CYP2E1—female reproductive system—urinary bladder cancer	0.000267	0.00421	CbGeAlD
Dexamethasone—CYP1A1—vagina—urinary bladder cancer	0.000265	0.00417	CbGeAlD
Dexamethasone—CYP2D6—renal system—urinary bladder cancer	0.000264	0.00416	CbGeAlD
Dexamethasone—CYP19A1—lymph node—urinary bladder cancer	0.000259	0.00408	CbGeAlD
Dexamethasone—CYP3A5—vagina—urinary bladder cancer	0.000259	0.00408	CbGeAlD
Dexamethasone—CYP2B6—vagina—urinary bladder cancer	0.000257	0.00405	CbGeAlD
Dexamethasone—NR3C1—vagina—urinary bladder cancer	0.000257	0.00405	CbGeAlD
Dexamethasone—ABCC2—lymph node—urinary bladder cancer	0.000248	0.0039	CbGeAlD
Dexamethasone—PTGS2—female reproductive system—urinary bladder cancer	0.000246	0.00387	CbGeAlD
Dexamethasone—CYP1B1—lymph node—urinary bladder cancer	0.000242	0.00382	CbGeAlD
Dexamethasone—ABCB1—seminal vesicle—urinary bladder cancer	0.000236	0.00371	CbGeAlD
Dexamethasone—PTGS2—vagina—urinary bladder cancer	0.000223	0.0035	CbGeAlD
Dexamethasone—CYP3A4—female reproductive system—urinary bladder cancer	0.000215	0.00338	CbGeAlD
Dexamethasone—CYP2D6—female reproductive system—urinary bladder cancer	0.000212	0.00333	CbGeAlD
Dexamethasone—ABCB1—epithelium—urinary bladder cancer	0.000205	0.00322	CbGeAlD
Dexamethasone—ABCB1—renal system—urinary bladder cancer	0.00019	0.00299	CbGeAlD
Dexamethasone—ABCB1—urethra—urinary bladder cancer	0.000187	0.00294	CbGeAlD
Dexamethasone—ABCG2—lymph node—urinary bladder cancer	0.000181	0.00284	CbGeAlD
Dexamethasone—CYP1A1—lymph node—urinary bladder cancer	0.000171	0.0027	CbGeAlD
Dexamethasone—NR3C1—lymph node—urinary bladder cancer	0.000166	0.00262	CbGeAlD
Dexamethasone—ABCB1—female reproductive system—urinary bladder cancer	0.000152	0.0024	CbGeAlD
Dexamethasone—PTGS2—lymph node—urinary bladder cancer	0.000144	0.00227	CbGeAlD
Dexamethasone—ABCB1—vagina—urinary bladder cancer	0.000138	0.00217	CbGeAlD
Dexamethasone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000108	0.000841	CcSEcCtD
Dexamethasone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000107	0.000838	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000107	0.000836	CcSEcCtD
Dexamethasone—Dry skin—Epirubicin—urinary bladder cancer	0.000107	0.000833	CcSEcCtD
Dexamethasone—Insomnia—Fluorouracil—urinary bladder cancer	0.000106	0.00083	CcSEcCtD
Dexamethasone—Anorexia—Cisplatin—urinary bladder cancer	0.000106	0.000829	CcSEcCtD
Dexamethasone—Affect lability—Doxorubicin—urinary bladder cancer	0.000106	0.000827	CcSEcCtD
Dexamethasone—Migraine—Doxorubicin—urinary bladder cancer	0.000106	0.000827	CcSEcCtD
Dexamethasone—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000106	0.000827	CcSEcCtD
Dexamethasone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000106	0.000824	CcSEcCtD
Dexamethasone—Discomfort—Etoposide—urinary bladder cancer	0.000105	0.000821	CcSEcCtD
Dexamethasone—Hypotension—Cisplatin—urinary bladder cancer	0.000104	0.000813	CcSEcCtD
Dexamethasone—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000104	0.000811	CcSEcCtD
Dexamethasone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000104	0.000807	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000103	0.000805	CcSEcCtD
Dexamethasone—Fatigue—Gemcitabine—urinary bladder cancer	0.000103	0.000804	CcSEcCtD
Dexamethasone—Muscular weakness—Epirubicin—urinary bladder cancer	0.000103	0.000801	CcSEcCtD
Dexamethasone—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000103	0.000799	CcSEcCtD
Dexamethasone—Pain—Gemcitabine—urinary bladder cancer	0.000102	0.000798	CcSEcCtD
Dexamethasone—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000102	0.000797	CcSEcCtD
Dexamethasone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000102	0.000797	CcSEcCtD
Dexamethasone—Mood swings—Doxorubicin—urinary bladder cancer	0.000102	0.000796	CcSEcCtD
Dexamethasone—Asthenia—Thiotepa—urinary bladder cancer	0.000102	0.000796	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000102	0.000792	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000102	0.000792	CcSEcCtD
Dexamethasone—Infection—Etoposide—urinary bladder cancer	0.000102	0.000791	CcSEcCtD
Dexamethasone—Pruritus—Thiotepa—urinary bladder cancer	0.000101	0.000785	CcSEcCtD
Dexamethasone—Pain—Fluorouracil—urinary bladder cancer	0.000101	0.000784	CcSEcCtD
Dexamethasone—Paraesthesia—Cisplatin—urinary bladder cancer	0.0001	0.000781	CcSEcCtD
Dexamethasone—Thrombocytopenia—Etoposide—urinary bladder cancer	0.0001	0.00078	CcSEcCtD
Dexamethasone—Tachycardia—Etoposide—urinary bladder cancer	9.97e-05	0.000777	CcSEcCtD
Dexamethasone—Dry skin—Doxorubicin—urinary bladder cancer	9.88e-05	0.000771	CcSEcCtD
Dexamethasone—Hyperhidrosis—Etoposide—urinary bladder cancer	9.88e-05	0.00077	CcSEcCtD
Dexamethasone—Feeling abnormal—Gemcitabine—urinary bladder cancer	9.86e-05	0.000769	CcSEcCtD
Dexamethasone—Hypokalaemia—Doxorubicin—urinary bladder cancer	9.81e-05	0.000765	CcSEcCtD
Dexamethasone—Anorexia—Etoposide—urinary bladder cancer	9.74e-05	0.000759	CcSEcCtD
Dexamethasone—Diarrhoea—Thiotepa—urinary bladder cancer	9.73e-05	0.000759	CcSEcCtD
Dexamethasone—Decreased appetite—Cisplatin—urinary bladder cancer	9.69e-05	0.000756	CcSEcCtD
Dexamethasone—Feeling abnormal—Fluorouracil—urinary bladder cancer	9.69e-05	0.000756	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	9.63e-05	0.000751	CcSEcCtD
Dexamethasone—Hypotension—Etoposide—urinary bladder cancer	9.55e-05	0.000744	CcSEcCtD
Dexamethasone—Pain—Cisplatin—urinary bladder cancer	9.54e-05	0.000744	CcSEcCtD
Dexamethasone—Muscular weakness—Doxorubicin—urinary bladder cancer	9.51e-05	0.000741	CcSEcCtD
Dexamethasone—Body temperature increased—Gemcitabine—urinary bladder cancer	9.46e-05	0.000737	CcSEcCtD
Dexamethasone—Dizziness—Thiotepa—urinary bladder cancer	9.41e-05	0.000733	CcSEcCtD
Dexamethasone—Urticaria—Fluorouracil—urinary bladder cancer	9.35e-05	0.000729	CcSEcCtD
Dexamethasone—Conjunctivitis—Methotrexate—urinary bladder cancer	9.33e-05	0.000727	CcSEcCtD
Dexamethasone—Body temperature increased—Fluorouracil—urinary bladder cancer	9.3e-05	0.000725	CcSEcCtD
Dexamethasone—Feeling abnormal—Cisplatin—urinary bladder cancer	9.19e-05	0.000717	CcSEcCtD
Dexamethasone—Paraesthesia—Etoposide—urinary bladder cancer	9.17e-05	0.000715	CcSEcCtD
Dexamethasone—Weight increased—Epirubicin—urinary bladder cancer	9.17e-05	0.000715	CcSEcCtD
Dexamethasone—Weight decreased—Epirubicin—urinary bladder cancer	9.11e-05	0.00071	CcSEcCtD
Dexamethasone—Hyperglycaemia—Epirubicin—urinary bladder cancer	9.08e-05	0.000708	CcSEcCtD
Dexamethasone—Vomiting—Thiotepa—urinary bladder cancer	9.04e-05	0.000705	CcSEcCtD
Dexamethasone—Rash—Thiotepa—urinary bladder cancer	8.97e-05	0.000699	CcSEcCtD
Dexamethasone—Dermatitis—Thiotepa—urinary bladder cancer	8.96e-05	0.000699	CcSEcCtD
Dexamethasone—Headache—Thiotepa—urinary bladder cancer	8.91e-05	0.000695	CcSEcCtD
Dexamethasone—ABCB1—lymph node—urinary bladder cancer	8.9e-05	0.0014	CbGeAlD
Dexamethasone—Decreased appetite—Etoposide—urinary bladder cancer	8.88e-05	0.000692	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	8.82e-05	0.000688	CcSEcCtD
Dexamethasone—Body temperature increased—Cisplatin—urinary bladder cancer	8.82e-05	0.000687	CcSEcCtD
Dexamethasone—Fatigue—Etoposide—urinary bladder cancer	8.81e-05	0.000687	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Epirubicin—urinary bladder cancer	8.8e-05	0.000686	CcSEcCtD
Dexamethasone—Pain—Etoposide—urinary bladder cancer	8.74e-05	0.000681	CcSEcCtD
Dexamethasone—Conjunctivitis—Epirubicin—urinary bladder cancer	8.73e-05	0.000681	CcSEcCtD
Dexamethasone—Haemoglobin—Methotrexate—urinary bladder cancer	8.66e-05	0.000675	CcSEcCtD
Dexamethasone—Haemorrhage—Methotrexate—urinary bladder cancer	8.61e-05	0.000672	CcSEcCtD
Dexamethasone—Asthenia—Gemcitabine—urinary bladder cancer	8.58e-05	0.000669	CcSEcCtD
Dexamethasone—Weight increased—Doxorubicin—urinary bladder cancer	8.48e-05	0.000661	CcSEcCtD
Dexamethasone—Pruritus—Gemcitabine—urinary bladder cancer	8.47e-05	0.00066	CcSEcCtD
Dexamethasone—Nausea—Thiotepa—urinary bladder cancer	8.45e-05	0.000659	CcSEcCtD
Dexamethasone—Weight decreased—Doxorubicin—urinary bladder cancer	8.43e-05	0.000657	CcSEcCtD
Dexamethasone—Feeling abnormal—Etoposide—urinary bladder cancer	8.42e-05	0.000656	CcSEcCtD
Dexamethasone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	8.41e-05	0.000655	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Etoposide—urinary bladder cancer	8.35e-05	0.000651	CcSEcCtD
Dexamethasone—Pruritus—Fluorouracil—urinary bladder cancer	8.32e-05	0.000649	CcSEcCtD
Dexamethasone—Visual impairment—Methotrexate—urinary bladder cancer	8.3e-05	0.000647	CcSEcCtD
Dexamethasone—Bradycardia—Epirubicin—urinary bladder cancer	8.21e-05	0.00064	CcSEcCtD
Dexamethasone—Diarrhoea—Gemcitabine—urinary bladder cancer	8.19e-05	0.000638	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	8.14e-05	0.000635	CcSEcCtD
Dexamethasone—Urticaria—Etoposide—urinary bladder cancer	8.12e-05	0.000633	CcSEcCtD
Dexamethasone—Haemoglobin—Epirubicin—urinary bladder cancer	8.1e-05	0.000632	CcSEcCtD
Dexamethasone—Abdominal pain—Etoposide—urinary bladder cancer	8.08e-05	0.00063	CcSEcCtD
Dexamethasone—Body temperature increased—Etoposide—urinary bladder cancer	8.08e-05	0.00063	CcSEcCtD
Dexamethasone—Conjunctivitis—Doxorubicin—urinary bladder cancer	8.08e-05	0.00063	CcSEcCtD
Dexamethasone—Haemorrhage—Epirubicin—urinary bladder cancer	8.06e-05	0.000629	CcSEcCtD
Dexamethasone—Eye disorder—Methotrexate—urinary bladder cancer	8.05e-05	0.000628	CcSEcCtD
Dexamethasone—Diarrhoea—Fluorouracil—urinary bladder cancer	8.05e-05	0.000628	CcSEcCtD
Dexamethasone—Asthenia—Cisplatin—urinary bladder cancer	8e-05	0.000624	CcSEcCtD
Dexamethasone—Angiopathy—Methotrexate—urinary bladder cancer	7.82e-05	0.000609	CcSEcCtD
Dexamethasone—Dizziness—Fluorouracil—urinary bladder cancer	7.78e-05	0.000607	CcSEcCtD
Dexamethasone—Visual impairment—Epirubicin—urinary bladder cancer	7.77e-05	0.000606	CcSEcCtD
Dexamethasone—Diarrhoea—Cisplatin—urinary bladder cancer	7.63e-05	0.000595	CcSEcCtD
Dexamethasone—Alopecia—Methotrexate—urinary bladder cancer	7.61e-05	0.000593	CcSEcCtD
Dexamethasone—Vomiting—Gemcitabine—urinary bladder cancer	7.61e-05	0.000593	CcSEcCtD
Dexamethasone—Bradycardia—Doxorubicin—urinary bladder cancer	7.59e-05	0.000592	CcSEcCtD
Dexamethasone—Rash—Gemcitabine—urinary bladder cancer	7.54e-05	0.000588	CcSEcCtD
Dexamethasone—Dermatitis—Gemcitabine—urinary bladder cancer	7.54e-05	0.000588	CcSEcCtD
Dexamethasone—Eye disorder—Epirubicin—urinary bladder cancer	7.53e-05	0.000587	CcSEcCtD
Dexamethasone—Erythema—Methotrexate—urinary bladder cancer	7.5e-05	0.000585	CcSEcCtD
Dexamethasone—Haemoglobin—Doxorubicin—urinary bladder cancer	7.5e-05	0.000585	CcSEcCtD
Dexamethasone—Headache—Gemcitabine—urinary bladder cancer	7.5e-05	0.000584	CcSEcCtD
Dexamethasone—Vomiting—Fluorouracil—urinary bladder cancer	7.48e-05	0.000583	CcSEcCtD
Dexamethasone—Haemorrhage—Doxorubicin—urinary bladder cancer	7.46e-05	0.000582	CcSEcCtD
Dexamethasone—Rash—Fluorouracil—urinary bladder cancer	7.42e-05	0.000578	CcSEcCtD
Dexamethasone—Dermatitis—Fluorouracil—urinary bladder cancer	7.41e-05	0.000578	CcSEcCtD
Dexamethasone—Headache—Fluorouracil—urinary bladder cancer	7.37e-05	0.000575	CcSEcCtD
Dexamethasone—Asthenia—Etoposide—urinary bladder cancer	7.33e-05	0.000572	CcSEcCtD
Dexamethasone—Angiopathy—Epirubicin—urinary bladder cancer	7.31e-05	0.00057	CcSEcCtD
Dexamethasone—Pruritus—Etoposide—urinary bladder cancer	7.23e-05	0.000564	CcSEcCtD
Dexamethasone—Arrhythmia—Epirubicin—urinary bladder cancer	7.2e-05	0.000561	CcSEcCtD
Dexamethasone—Visual impairment—Doxorubicin—urinary bladder cancer	7.19e-05	0.00056	CcSEcCtD
Dexamethasone—Alopecia—Epirubicin—urinary bladder cancer	7.12e-05	0.000555	CcSEcCtD
Dexamethasone—Nausea—Gemcitabine—urinary bladder cancer	7.11e-05	0.000554	CcSEcCtD
Dexamethasone—Vomiting—Cisplatin—urinary bladder cancer	7.09e-05	0.000553	CcSEcCtD
Dexamethasone—Rash—Cisplatin—urinary bladder cancer	7.03e-05	0.000548	CcSEcCtD
Dexamethasone—Dermatitis—Cisplatin—urinary bladder cancer	7.03e-05	0.000548	CcSEcCtD
Dexamethasone—Erythema—Epirubicin—urinary bladder cancer	7.02e-05	0.000547	CcSEcCtD
Dexamethasone—Diarrhoea—Etoposide—urinary bladder cancer	6.99e-05	0.000545	CcSEcCtD
Dexamethasone—Nausea—Fluorouracil—urinary bladder cancer	6.99e-05	0.000545	CcSEcCtD
Dexamethasone—Eye disorder—Doxorubicin—urinary bladder cancer	6.97e-05	0.000543	CcSEcCtD
Dexamethasone—Ill-defined disorder—Methotrexate—urinary bladder cancer	6.96e-05	0.000542	CcSEcCtD
Dexamethasone—Angiopathy—Doxorubicin—urinary bladder cancer	6.77e-05	0.000528	CcSEcCtD
Dexamethasone—Malaise—Methotrexate—urinary bladder cancer	6.76e-05	0.000527	CcSEcCtD
Dexamethasone—Dizziness—Etoposide—urinary bladder cancer	6.76e-05	0.000527	CcSEcCtD
Dexamethasone—Vertigo—Methotrexate—urinary bladder cancer	6.74e-05	0.000525	CcSEcCtD
Dexamethasone—Arrhythmia—Doxorubicin—urinary bladder cancer	6.66e-05	0.00052	CcSEcCtD
Dexamethasone—Nausea—Cisplatin—urinary bladder cancer	6.62e-05	0.000516	CcSEcCtD
Dexamethasone—Alopecia—Doxorubicin—urinary bladder cancer	6.59e-05	0.000514	CcSEcCtD
Dexamethasone—Ill-defined disorder—Epirubicin—urinary bladder cancer	6.51e-05	0.000508	CcSEcCtD
Dexamethasone—Convulsion—Methotrexate—urinary bladder cancer	6.5e-05	0.000507	CcSEcCtD
Dexamethasone—Vomiting—Etoposide—urinary bladder cancer	6.5e-05	0.000506	CcSEcCtD
Dexamethasone—Erythema—Doxorubicin—urinary bladder cancer	6.49e-05	0.000506	CcSEcCtD
Dexamethasone—Rash—Etoposide—urinary bladder cancer	6.44e-05	0.000502	CcSEcCtD
Dexamethasone—Dermatitis—Etoposide—urinary bladder cancer	6.44e-05	0.000502	CcSEcCtD
Dexamethasone—Headache—Etoposide—urinary bladder cancer	6.4e-05	0.000499	CcSEcCtD
Dexamethasone—Myalgia—Methotrexate—urinary bladder cancer	6.38e-05	0.000498	CcSEcCtD
Dexamethasone—Malaise—Epirubicin—urinary bladder cancer	6.33e-05	0.000493	CcSEcCtD
Dexamethasone—Discomfort—Methotrexate—urinary bladder cancer	6.31e-05	0.000492	CcSEcCtD
Dexamethasone—Vertigo—Epirubicin—urinary bladder cancer	6.3e-05	0.000492	CcSEcCtD
Dexamethasone—Syncope—Epirubicin—urinary bladder cancer	6.29e-05	0.000491	CcSEcCtD
Dexamethasone—Loss of consciousness—Epirubicin—urinary bladder cancer	6.17e-05	0.000481	CcSEcCtD
Dexamethasone—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.12e-05	0.000477	CcSEcCtD
Dexamethasone—Convulsion—Epirubicin—urinary bladder cancer	6.08e-05	0.000474	CcSEcCtD
Dexamethasone—Infection—Methotrexate—urinary bladder cancer	6.08e-05	0.000474	CcSEcCtD
Dexamethasone—Nausea—Etoposide—urinary bladder cancer	6.07e-05	0.000473	CcSEcCtD
Dexamethasone—Hypertension—Epirubicin—urinary bladder cancer	6.06e-05	0.000472	CcSEcCtD
Dexamethasone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	6.02e-05	0.00047	CcSEcCtD
Dexamethasone—Nervous system disorder—Methotrexate—urinary bladder cancer	6e-05	0.000468	CcSEcCtD
Dexamethasone—Thrombocytopenia—Methotrexate—urinary bladder cancer	5.99e-05	0.000467	CcSEcCtD
Dexamethasone—Myalgia—Epirubicin—urinary bladder cancer	5.97e-05	0.000466	CcSEcCtD
Dexamethasone—Anxiety—Epirubicin—urinary bladder cancer	5.95e-05	0.000464	CcSEcCtD
Dexamethasone—Hyperhidrosis—Methotrexate—urinary bladder cancer	5.92e-05	0.000461	CcSEcCtD
Dexamethasone—Discomfort—Epirubicin—urinary bladder cancer	5.9e-05	0.00046	CcSEcCtD
Dexamethasone—Malaise—Doxorubicin—urinary bladder cancer	5.86e-05	0.000457	CcSEcCtD
Dexamethasone—Vertigo—Doxorubicin—urinary bladder cancer	5.83e-05	0.000455	CcSEcCtD
Dexamethasone—Anorexia—Methotrexate—urinary bladder cancer	5.83e-05	0.000455	CcSEcCtD
Dexamethasone—Syncope—Doxorubicin—urinary bladder cancer	5.82e-05	0.000454	CcSEcCtD
Dexamethasone—Anaphylactic shock—Epirubicin—urinary bladder cancer	5.73e-05	0.000447	CcSEcCtD
Dexamethasone—Oedema—Epirubicin—urinary bladder cancer	5.73e-05	0.000447	CcSEcCtD
Dexamethasone—Hypotension—Methotrexate—urinary bladder cancer	5.72e-05	0.000446	CcSEcCtD
Dexamethasone—Loss of consciousness—Doxorubicin—urinary bladder cancer	5.71e-05	0.000445	CcSEcCtD
Dexamethasone—Infection—Epirubicin—urinary bladder cancer	5.69e-05	0.000444	CcSEcCtD
Dexamethasone—Shock—Epirubicin—urinary bladder cancer	5.63e-05	0.000439	CcSEcCtD
Dexamethasone—Convulsion—Doxorubicin—urinary bladder cancer	5.63e-05	0.000439	CcSEcCtD
Dexamethasone—Nervous system disorder—Epirubicin—urinary bladder cancer	5.62e-05	0.000438	CcSEcCtD
Dexamethasone—Thrombocytopenia—Epirubicin—urinary bladder cancer	5.61e-05	0.000437	CcSEcCtD
Dexamethasone—Hypertension—Doxorubicin—urinary bladder cancer	5.61e-05	0.000437	CcSEcCtD
Dexamethasone—Tachycardia—Epirubicin—urinary bladder cancer	5.59e-05	0.000436	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	5.58e-05	0.000435	CcSEcCtD
Dexamethasone—Hyperhidrosis—Epirubicin—urinary bladder cancer	5.54e-05	0.000432	CcSEcCtD
Dexamethasone—Insomnia—Methotrexate—urinary bladder cancer	5.54e-05	0.000432	CcSEcCtD
Dexamethasone—Myalgia—Doxorubicin—urinary bladder cancer	5.53e-05	0.000431	CcSEcCtD
Dexamethasone—Anxiety—Doxorubicin—urinary bladder cancer	5.51e-05	0.00043	CcSEcCtD
Dexamethasone—Paraesthesia—Methotrexate—urinary bladder cancer	5.5e-05	0.000428	CcSEcCtD
Dexamethasone—Discomfort—Doxorubicin—urinary bladder cancer	5.46e-05	0.000426	CcSEcCtD
Dexamethasone—Anorexia—Epirubicin—urinary bladder cancer	5.46e-05	0.000426	CcSEcCtD
Dexamethasone—Dyspepsia—Methotrexate—urinary bladder cancer	5.39e-05	0.00042	CcSEcCtD
Dexamethasone—Hypotension—Epirubicin—urinary bladder cancer	5.35e-05	0.000417	CcSEcCtD
Dexamethasone—Decreased appetite—Methotrexate—urinary bladder cancer	5.32e-05	0.000415	CcSEcCtD
Dexamethasone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.3e-05	0.000413	CcSEcCtD
Dexamethasone—Oedema—Doxorubicin—urinary bladder cancer	5.3e-05	0.000413	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.28e-05	0.000412	CcSEcCtD
Dexamethasone—Fatigue—Methotrexate—urinary bladder cancer	5.28e-05	0.000411	CcSEcCtD
Dexamethasone—Infection—Doxorubicin—urinary bladder cancer	5.26e-05	0.00041	CcSEcCtD
Dexamethasone—Pain—Methotrexate—urinary bladder cancer	5.23e-05	0.000408	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.22e-05	0.000407	CcSEcCtD
Dexamethasone—Shock—Doxorubicin—urinary bladder cancer	5.21e-05	0.000406	CcSEcCtD
Dexamethasone—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.2e-05	0.000405	CcSEcCtD
Dexamethasone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.19e-05	0.000405	CcSEcCtD
Dexamethasone—Insomnia—Epirubicin—urinary bladder cancer	5.18e-05	0.000404	CcSEcCtD
Dexamethasone—Tachycardia—Doxorubicin—urinary bladder cancer	5.17e-05	0.000403	CcSEcCtD
Dexamethasone—Paraesthesia—Epirubicin—urinary bladder cancer	5.14e-05	0.000401	CcSEcCtD
Dexamethasone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.12e-05	0.000399	CcSEcCtD
Dexamethasone—Anorexia—Doxorubicin—urinary bladder cancer	5.05e-05	0.000394	CcSEcCtD
Dexamethasone—Feeling abnormal—Methotrexate—urinary bladder cancer	5.04e-05	0.000393	CcSEcCtD
Dexamethasone—Dyspepsia—Epirubicin—urinary bladder cancer	5.04e-05	0.000393	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5e-05	0.00039	CcSEcCtD
Dexamethasone—Decreased appetite—Epirubicin—urinary bladder cancer	4.98e-05	0.000388	CcSEcCtD
Dexamethasone—Hypotension—Doxorubicin—urinary bladder cancer	4.95e-05	0.000386	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.94e-05	0.000386	CcSEcCtD
Dexamethasone—Fatigue—Epirubicin—urinary bladder cancer	4.94e-05	0.000385	CcSEcCtD
Dexamethasone—Pain—Epirubicin—urinary bladder cancer	4.9e-05	0.000382	CcSEcCtD
Dexamethasone—Urticaria—Methotrexate—urinary bladder cancer	4.86e-05	0.000379	CcSEcCtD
Dexamethasone—Abdominal pain—Methotrexate—urinary bladder cancer	4.84e-05	0.000377	CcSEcCtD
Dexamethasone—Body temperature increased—Methotrexate—urinary bladder cancer	4.84e-05	0.000377	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	4.83e-05	0.000376	CcSEcCtD
Dexamethasone—Insomnia—Doxorubicin—urinary bladder cancer	4.79e-05	0.000374	CcSEcCtD
Dexamethasone—Paraesthesia—Doxorubicin—urinary bladder cancer	4.76e-05	0.000371	CcSEcCtD
Dexamethasone—Feeling abnormal—Epirubicin—urinary bladder cancer	4.72e-05	0.000368	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	4.68e-05	0.000365	CcSEcCtD
Dexamethasone—Dyspepsia—Doxorubicin—urinary bladder cancer	4.66e-05	0.000364	CcSEcCtD
Dexamethasone—Decreased appetite—Doxorubicin—urinary bladder cancer	4.61e-05	0.000359	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	4.57e-05	0.000357	CcSEcCtD
Dexamethasone—Fatigue—Doxorubicin—urinary bladder cancer	4.57e-05	0.000356	CcSEcCtD
Dexamethasone—Urticaria—Epirubicin—urinary bladder cancer	4.55e-05	0.000355	CcSEcCtD
Dexamethasone—Pain—Doxorubicin—urinary bladder cancer	4.53e-05	0.000353	CcSEcCtD
Dexamethasone—Abdominal pain—Epirubicin—urinary bladder cancer	4.53e-05	0.000353	CcSEcCtD
Dexamethasone—Body temperature increased—Epirubicin—urinary bladder cancer	4.53e-05	0.000353	CcSEcCtD
Dexamethasone—Asthenia—Methotrexate—urinary bladder cancer	4.39e-05	0.000342	CcSEcCtD
Dexamethasone—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.37e-05	0.00034	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.33e-05	0.000338	CcSEcCtD
Dexamethasone—Pruritus—Methotrexate—urinary bladder cancer	4.33e-05	0.000338	CcSEcCtD
Dexamethasone—Urticaria—Doxorubicin—urinary bladder cancer	4.21e-05	0.000328	CcSEcCtD
Dexamethasone—Abdominal pain—Doxorubicin—urinary bladder cancer	4.19e-05	0.000327	CcSEcCtD
Dexamethasone—Body temperature increased—Doxorubicin—urinary bladder cancer	4.19e-05	0.000327	CcSEcCtD
Dexamethasone—Diarrhoea—Methotrexate—urinary bladder cancer	4.19e-05	0.000326	CcSEcCtD
Dexamethasone—Asthenia—Epirubicin—urinary bladder cancer	4.11e-05	0.00032	CcSEcCtD
Dexamethasone—Pruritus—Epirubicin—urinary bladder cancer	4.05e-05	0.000316	CcSEcCtD
Dexamethasone—Dizziness—Methotrexate—urinary bladder cancer	4.05e-05	0.000316	CcSEcCtD
Dexamethasone—Diarrhoea—Epirubicin—urinary bladder cancer	3.92e-05	0.000306	CcSEcCtD
Dexamethasone—Vomiting—Methotrexate—urinary bladder cancer	3.89e-05	0.000303	CcSEcCtD
Dexamethasone—Rash—Methotrexate—urinary bladder cancer	3.86e-05	0.000301	CcSEcCtD
Dexamethasone—Dermatitis—Methotrexate—urinary bladder cancer	3.86e-05	0.000301	CcSEcCtD
Dexamethasone—Headache—Methotrexate—urinary bladder cancer	3.83e-05	0.000299	CcSEcCtD
Dexamethasone—Asthenia—Doxorubicin—urinary bladder cancer	3.8e-05	0.000296	CcSEcCtD
Dexamethasone—Dizziness—Epirubicin—urinary bladder cancer	3.79e-05	0.000295	CcSEcCtD
Dexamethasone—Pruritus—Doxorubicin—urinary bladder cancer	3.75e-05	0.000292	CcSEcCtD
Dexamethasone—Vomiting—Epirubicin—urinary bladder cancer	3.64e-05	0.000284	CcSEcCtD
Dexamethasone—Nausea—Methotrexate—urinary bladder cancer	3.64e-05	0.000283	CcSEcCtD
Dexamethasone—Diarrhoea—Doxorubicin—urinary bladder cancer	3.63e-05	0.000283	CcSEcCtD
Dexamethasone—Rash—Epirubicin—urinary bladder cancer	3.61e-05	0.000282	CcSEcCtD
Dexamethasone—Dermatitis—Epirubicin—urinary bladder cancer	3.61e-05	0.000281	CcSEcCtD
Dexamethasone—Headache—Epirubicin—urinary bladder cancer	3.59e-05	0.00028	CcSEcCtD
Dexamethasone—Dizziness—Doxorubicin—urinary bladder cancer	3.5e-05	0.000273	CcSEcCtD
Dexamethasone—Nausea—Epirubicin—urinary bladder cancer	3.4e-05	0.000265	CcSEcCtD
Dexamethasone—Vomiting—Doxorubicin—urinary bladder cancer	3.37e-05	0.000263	CcSEcCtD
Dexamethasone—Rash—Doxorubicin—urinary bladder cancer	3.34e-05	0.000261	CcSEcCtD
Dexamethasone—Dermatitis—Doxorubicin—urinary bladder cancer	3.34e-05	0.00026	CcSEcCtD
Dexamethasone—Headache—Doxorubicin—urinary bladder cancer	3.32e-05	0.000259	CcSEcCtD
Dexamethasone—Nausea—Doxorubicin—urinary bladder cancer	3.15e-05	0.000245	CcSEcCtD
Dexamethasone—ANXA1—Signaling Pathways—TP53—urinary bladder cancer	5.49e-06	4.19e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.47e-06	4.18e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	5.47e-06	4.18e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—RRM2—urinary bladder cancer	5.47e-06	4.18e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—MTHFR—urinary bladder cancer	5.43e-06	4.15e-05	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—EP300—urinary bladder cancer	5.42e-06	4.14e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—NQO1—urinary bladder cancer	5.42e-06	4.14e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.42e-06	4.14e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	5.38e-06	4.11e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	5.37e-06	4.11e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—ENO2—urinary bladder cancer	5.37e-06	4.11e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—GPX1—urinary bladder cancer	5.34e-06	4.08e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	5.34e-06	4.08e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	5.34e-06	4.08e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.26e-06	4.02e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.26e-06	4.02e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—ERCC2—urinary bladder cancer	5.26e-06	4.02e-05	CbGpPWpGaD
Dexamethasone—ANXA1—Signaling Pathways—HRAS—urinary bladder cancer	5.25e-06	4.01e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	5.25e-06	4.01e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PTGS2—urinary bladder cancer	5.24e-06	4e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	5.21e-06	3.98e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—PTEN—urinary bladder cancer	5.2e-06	3.97e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.17e-06	3.95e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—ERBB2—urinary bladder cancer	5.15e-06	3.94e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—PTEN—urinary bladder cancer	5.15e-06	3.93e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—GSTP1—urinary bladder cancer	5.1e-06	3.89e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ENO2—urinary bladder cancer	5.06e-06	3.87e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	5.06e-06	3.87e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PPARG—urinary bladder cancer	5.02e-06	3.84e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.02e-06	3.84e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.02e-06	3.84e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.99e-06	3.81e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—NQO1—urinary bladder cancer	4.97e-06	3.8e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—EP300—urinary bladder cancer	4.96e-06	3.79e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MTHFR—urinary bladder cancer	4.94e-06	3.78e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.93e-06	3.77e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	4.93e-06	3.77e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—TERT—urinary bladder cancer	4.93e-06	3.77e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.91e-06	3.75e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—EP300—urinary bladder cancer	4.91e-06	3.75e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	4.9e-06	3.74e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	4.89e-06	3.73e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.88e-06	3.73e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.87e-06	3.72e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PPARG—urinary bladder cancer	4.84e-06	3.7e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	4.83e-06	3.69e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.82e-06	3.69e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	4.8e-06	3.67e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.79e-06	3.66e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	4.79e-06	3.66e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—TYMS—urinary bladder cancer	4.74e-06	3.62e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—GSTM1—urinary bladder cancer	4.68e-06	3.58e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—NCOR1—urinary bladder cancer	4.68e-06	3.58e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—IL2—urinary bladder cancer	4.67e-06	3.57e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	4.65e-06	3.55e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.59e-06	3.51e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.58e-06	3.5e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PTEN—urinary bladder cancer	4.57e-06	3.49e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CCND1—urinary bladder cancer	4.55e-06	3.48e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—TYMS—urinary bladder cancer	4.55e-06	3.48e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	4.52e-06	3.46e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—FGFR3—urinary bladder cancer	4.52e-06	3.46e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	4.5e-06	3.44e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	4.5e-06	3.44e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—GPX1—urinary bladder cancer	4.49e-06	3.43e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—TYMS—urinary bladder cancer	4.46e-06	3.41e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—TYMS—urinary bladder cancer	4.45e-06	3.4e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4.44e-06	3.39e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MMP9—urinary bladder cancer	4.42e-06	3.38e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	4.41e-06	3.37e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	4.41e-06	3.37e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	4.41e-06	3.37e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—ERCC2—urinary bladder cancer	4.4e-06	3.36e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PPARG—urinary bladder cancer	4.4e-06	3.36e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	4.4e-06	3.36e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	4.4e-06	3.36e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PTEN—urinary bladder cancer	4.4e-06	3.36e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.38e-06	3.34e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	4.37e-06	3.34e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PPARG—urinary bladder cancer	4.36e-06	3.33e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—EP300—urinary bladder cancer	4.36e-06	3.33e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—NQO1—urinary bladder cancer	4.33e-06	3.31e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—GPX1—urinary bladder cancer	4.31e-06	3.29e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.31e-06	3.29e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	4.23e-06	3.23e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—CREBBP—urinary bladder cancer	4.23e-06	3.23e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—GPX1—urinary bladder cancer	4.22e-06	3.23e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—GPX1—urinary bladder cancer	4.21e-06	3.22e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.21e-06	3.21e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—TYMS—urinary bladder cancer	4.21e-06	3.21e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—EP300—urinary bladder cancer	4.19e-06	3.2e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	4.19e-06	3.2e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	4.16e-06	3.18e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	4.16e-06	3.18e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	4.15e-06	3.17e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	4.15e-06	3.17e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.14e-06	3.16e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—MTHFR—urinary bladder cancer	4.14e-06	3.16e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	4.14e-06	3.16e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	4.08e-06	3.12e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—SRC—urinary bladder cancer	4.08e-06	3.11e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.05e-06	3.09e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.01e-06	3.07e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PPARG—urinary bladder cancer	4e-06	3.05e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—GPX1—urinary bladder cancer	3.98e-06	3.04e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	3.98e-06	3.04e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	3.95e-06	3.02e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.93e-06	3e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	3.91e-06	2.99e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	3.9e-06	2.98e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	3.89e-06	2.97e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—TYMS—urinary bladder cancer	3.86e-06	2.95e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CREBBP—urinary bladder cancer	3.85e-06	2.94e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	3.84e-06	2.93e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	3.81e-06	2.91e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	3.81e-06	2.91e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	3.81e-06	2.91e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	3.81e-06	2.91e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.76e-06	2.87e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.7e-06	2.83e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	3.67e-06	2.81e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MYC—urinary bladder cancer	3.65e-06	2.79e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—GPX1—urinary bladder cancer	3.65e-06	2.79e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—EP300—urinary bladder cancer	3.64e-06	2.78e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	3.61e-06	2.76e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	3.58e-06	2.74e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.58e-06	2.74e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.58e-06	2.73e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—EGFR—urinary bladder cancer	3.57e-06	2.73e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—RHOA—urinary bladder cancer	3.48e-06	2.66e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PTGS2—urinary bladder cancer	3.46e-06	2.64e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PTEN—urinary bladder cancer	3.45e-06	2.63e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.44e-06	2.63e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	3.43e-06	2.62e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.42e-06	2.62e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.4e-06	2.6e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.4e-06	2.6e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.4e-06	2.6e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—KRAS—urinary bladder cancer	3.38e-06	2.58e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.38e-06	2.58e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	3.37e-06	2.57e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—TYMS—urinary bladder cancer	3.36e-06	2.57e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PPARG—urinary bladder cancer	3.36e-06	2.56e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	3.32e-06	2.54e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	3.32e-06	2.54e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PTEN—urinary bladder cancer	3.32e-06	2.54e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.31e-06	2.53e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.31e-06	2.53e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—EP300—urinary bladder cancer	3.29e-06	2.51e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.27e-06	2.49e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GPX1—urinary bladder cancer	3.26e-06	2.49e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—MYC—urinary bladder cancer	3.25e-06	2.48e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PPARG—urinary bladder cancer	3.23e-06	2.46e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—CREBBP—urinary bladder cancer	3.22e-06	2.46e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—ERBB2—urinary bladder cancer	3.22e-06	2.46e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.21e-06	2.45e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	3.2e-06	2.44e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GPX1—urinary bladder cancer	3.18e-06	2.43e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.17e-06	2.42e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—EP300—urinary bladder cancer	3.17e-06	2.42e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PPARG—urinary bladder cancer	3.16e-06	2.41e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PPARG—urinary bladder cancer	3.15e-06	2.41e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	3.15e-06	2.4e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.14e-06	2.4e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.13e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.13e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	3.12e-06	2.38e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.1e-06	2.37e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.1e-06	2.37e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	3.1e-06	2.37e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	3.04e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	3.03e-06	2.31e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PTEN—urinary bladder cancer	3.02e-06	2.31e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	3.01e-06	2.3e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—TP53—urinary bladder cancer	3e-06	2.29e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3e-06	2.29e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PTEN—urinary bladder cancer	2.99e-06	2.29e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PPARG—urinary bladder cancer	2.98e-06	2.28e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.97e-06	2.27e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.94e-06	2.25e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	2.93e-06	2.24e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.92e-06	2.23e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—EP300—urinary bladder cancer	2.88e-06	2.2e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—HRAS—urinary bladder cancer	2.87e-06	2.19e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	2.86e-06	2.19e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—EP300—urinary bladder cancer	2.85e-06	2.18e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.77e-06	2.11e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CDKN1A—urinary bladder cancer	2.76e-06	2.11e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PTEN—urinary bladder cancer	2.75e-06	2.1e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PTEN—urinary bladder cancer	2.74e-06	2.1e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.74e-06	2.09e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PPARG—urinary bladder cancer	2.73e-06	2.09e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.67e-06	2.04e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	2.62e-06	2e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—EP300—urinary bladder cancer	2.62e-06	2e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—EP300—urinary bladder cancer	2.62e-06	2e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—SRC—urinary bladder cancer	2.55e-06	1.95e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	2.54e-06	1.94e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	2.49e-06	1.9e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	2.48e-06	1.89e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.44e-06	1.86e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PPARG—urinary bladder cancer	2.38e-06	1.82e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	2.34e-06	1.79e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.34e-06	1.79e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PTEN—urinary bladder cancer	2.3e-06	1.76e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.29e-06	1.75e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MYC—urinary bladder cancer	2.29e-06	1.75e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.24e-06	1.71e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—EGFR—urinary bladder cancer	2.24e-06	1.71e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.23e-06	1.7e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.22e-06	1.7e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PTEN—urinary bladder cancer	2.21e-06	1.69e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—EP300—urinary bladder cancer	2.2e-06	1.68e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PTEN—urinary bladder cancer	2.17e-06	1.66e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	2.16e-06	1.65e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.15e-06	1.65e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	2.15e-06	1.64e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.14e-06	1.63e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—KRAS—urinary bladder cancer	2.11e-06	1.61e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—EP300—urinary bladder cancer	2.11e-06	1.61e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.07e-06	1.58e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—EP300—urinary bladder cancer	2.07e-06	1.58e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.06e-06	1.58e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.05e-06	1.56e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.05e-06	1.56e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PTEN—urinary bladder cancer	2.04e-06	1.56e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.96e-06	1.5e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—EP300—urinary bladder cancer	1.95e-06	1.49e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.92e-06	1.47e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.92e-06	1.46e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.87e-06	1.43e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.87e-06	1.43e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.81e-06	1.38e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—HRAS—urinary bladder cancer	1.79e-06	1.37e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.79e-06	1.37e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.76e-06	1.35e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.75e-06	1.34e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.67e-06	1.28e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.63e-06	1.25e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.6e-06	1.22e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—EP300—urinary bladder cancer	1.56e-06	1.19e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.54e-06	1.18e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.53e-06	1.16e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.47e-06	1.12e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.47e-06	1.12e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.45e-06	1.11e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.41e-06	1.08e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.15e-06	8.81e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.01e-06	7.68e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.59e-07	7.33e-06	CbGpPWpGaD
